Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MB-111
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mammoth Picks MB-111 as First Candidate, Adds Bob D. Brown to Board
Details : MB-111 is designed to permanently disrupt the expression of the APOC3 gene in the liver, and thus to reduce expression of ApoC-III protein. It is being investigated for FCS and SHTG.
Product Name : MB-111
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : MB-111
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $470.0 million
Deal Type : Collaboration
Regeneron and Mammoth Biosciences Partner to Develop CRISPR Gene Editing Therapies
Details : Under the collaboration, Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s delivery technologies are set to advance in vivo study in multiple tissue and cell types.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $100.0 million
April 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $470.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery Platform
Sponsor : Bayer AG
Deal Size : $1,040.0 million
Deal Type : Collaboration
Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
Details : Two companies will start their collaboration with a focus on developing in vivo gene-editing therapies for liver-targeted diseases. This agreement strengthens Bayer’s new cell and gene therapy platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
October 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery Platform
Sponsor : Bayer AG
Deal Size : $1,040.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Vertex Pharmaceuticals
Deal Size : $691.0 million
Deal Type : Collaboration
Details : The combination of Mammoth’s unique technology with Vertex’s unmatched experience in serious disease research and development will only accelerate programs with the goal of reaching patients with high unmet medical need.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $41.0 million
October 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Vertex Pharmaceuticals
Deal Size : $691.0 million
Deal Type : Collaboration